VIBISONE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vibisone, and when can generic versions of Vibisone launch?
Vibisone is a drug marketed by Fresenius Kabi Usa and is included in one NDA.
The generic ingredient in VIBISONE is cyanocobalamin. There are nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyanocobalamin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vibisone
A generic version of VIBISONE was approved as cyanocobalamin by PADAGIS ISRAEL on September 9th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VIBISONE?
- What are the global sales for VIBISONE?
- What is Average Wholesale Price for VIBISONE?
Summary for VIBISONE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Patent Applications: | 57 |
| DailyMed Link: | VIBISONE at DailyMed |
Pharmacology for VIBISONE
| Drug Class | Vitamin B12 |
US Patents and Regulatory Information for VIBISONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | VIBISONE | cyanocobalamin | INJECTABLE;INJECTION | 080557-003 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
